1. Home
  2. JBI vs ABUS Comparison

JBI vs ABUS Comparison

Compare JBI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janus International Group Inc.

JBI

Janus International Group Inc.

HOLD

Current Price

$4.86

Market Cap

987.0M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.19

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBI
ABUS
Founded
2002
2005
Country
United States
United States
Employees
N/A
19
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
987.0M
848.8M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
JBI
ABUS
Price
$4.86
$4.19
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$9.17
$5.00
AVG Volume (30 Days)
1.7M
1.6M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$9.36
N/A
Revenue Next Year
$3.16
$239.71
P/E Ratio
$12.96
$4.87
Revenue Growth
N/A
128.21
52 Week Low
$4.26
$3.04
52 Week High
$10.80
$5.10

Technical Indicators

Market Signals
Indicator
JBI
ABUS
Relative Strength Index (RSI) 38.80 41.74
Support Level N/A $3.68
Resistance Level $5.66 $4.62
Average True Range (ATR) 0.27 0.15
MACD -0.03 -0.01
Stochastic Oscillator 48.95 30.19

Price Performance

Historical Comparison
JBI
ABUS

About JBI Janus International Group Inc.

Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: